Rhumbline Advisers Mersana Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 166,846 shares of MRSN stock, worth $370,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares

166,846

Previous 176,063 5.24%

Holding current value

$370,398

Previous $353,000 10.76%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$1.23 - $2.25 $11,336 - $20,738	-9,217 Reduced 5.24%	166,846 $315,000
Q2 2024 Aug 01, 2024	SELL	$2.0 - $4.45 $5,780 - $12,860	-2,890 Reduced 1.61%	176,063 $353,000
Q1 2024 May 09, 2024	BUY	$2.16 - $5.94 $40,785 - $112,159	18,882 Added 11.8%	178,953 $801,000
Q4 2023 Feb 08, 2024	SELL	$1.11 - $2.34 $5 - $11	-5 Reduced -0.0%	160,071 $371,000
Q3 2023 Nov 09, 2023	SELL	$1.06 - $3.91 $5,082 - $18,748	-4,795 Reduced 2.91%	160,076 $203,000
Q2 2023 Aug 08, 2023	BUY	$3.08 - $9.55 $20,112 - $62,361	6,530 Added 4.12%	164,871 $542,000
Q1 2023 May 11, 2023	BUY	$4.0 - $7.02 $21,504 - $37,739	5,376 Added 3.51%	158,341 $651,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $29,741 - $41,375	5,264 Added 3.56%	152,965 $896,000
Q3 2022 Nov 10, 2022	BUY	$4.63 - $8.0 $56,286 - $97,256	12,157 Added 8.97%	147,701 $998,000
Q2 2022 Aug 11, 2022	BUY	$2.84 - $5.0 $158,071 - $278,295	55,659 Added 69.67%	135,544 $626,000
Q1 2022 May 12, 2022	SELL	$3.74 - $6.63 $3,336 - $5,913	-892 Reduced 1.1%	79,885 $319,000
Q4 2021 Feb 10, 2022	SELL	$5.48 - $9.86 $10,773 - $19,384	-1,966 Reduced 2.38%	80,777 $502,000
Q3 2021 Nov 12, 2021	BUY	$8.56 - $14.47 $20,621 - $34,858	2,409 Added 3.0%	82,743 $780,000
Q2 2021 Aug 05, 2021	BUY	$13.28 - $18.07 $165,495 - $225,188	12,462 Added 18.36%	80,334 $1.09 Million
Q1 2021 May 06, 2021	SELL	$15.31 - $26.52 $33,192 - $57,495	-2,168 Reduced 3.1%	67,872 $1.1 Million
Q4 2020 Feb 10, 2021	BUY	$16.84 - $27.59 $90,228 - $147,827	5,358 Added 8.28%	70,040 $1.86 Million
Q3 2020 Nov 12, 2020	SELL	$16.2 - $25.7 $72,381 - $114,827	-4,468 Reduced 6.46%	64,682 $1.2 Million
Q2 2020 Aug 13, 2020	BUY	$5.24 - $23.4 $83,604 - $373,347	15,955 Added 29.99%	69,150 $1.62 Million
Q1 2020 May 06, 2020	BUY	$4.41 - $9.28 $30,182 - $63,512	6,844 Added 14.77%	53,195 $310,000
Q4 2019 Feb 05, 2020	BUY	$1.45 - $6.73 $3,549 - $16,475	2,448 Added 5.58%	46,351 $266,000
Q3 2019 Oct 23, 2019	BUY	$1.54 - $4.2 $6,834 - $18,639	4,438 Added 11.25%	43,903 $69,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $87,183 - $145,305	22,704 Added 135.46%	39,465 $160,000
Q1 2019 May 01, 2019	BUY	$3.51 - $7.3 $2,313 - $4,810	659 Added 4.09%	16,761 $88,000
Q4 2018 Jan 31, 2019	BUY	$3.45 - $9.72 $17,560 - $49,474	5,090 Added 46.22%	16,102 $66,000
Q3 2018 Nov 07, 2018	SELL	$10.0 - $19.02 $7,750 - $14,740	-775 Reduced 6.58%	11,012 $110,000
Q2 2018 Aug 06, 2018	BUY	$14.2 - $22.68 $167,375 - $267,329	11,787 New	11,787 $211,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $216M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Mersana Therapeutics, Inc. Transaction History